What is Coave Therapeutics?
Headquartered in Paris, France, Coave Therapeutics—formerly known as Horama—is a specialized biotechnology company dedicated to the development of life-changing gene therapies. The firm operates at the intersection of advanced genetic engineering and clinical medicine, focusing specifically on rare diseases that affect the eye and the central nervous system. By utilizing its unique technological platforms, Coave aims to provide durable, transformative treatments for patients suffering from conditions that currently lack effective therapeutic options. The company's market position is bolstered by its deep expertise in viral vector design and its strategic focus on high-value, orphan disease indications.
How much funding has Coave Therapeutics raised?
Coave Therapeutics has raised a total of $92.1M across 3 funding rounds:
Series A
$35.1M
Series B
$25M
Series A
$32M
Series A (2019): $35.1M with participation from BioGeneration Ventures, Perceptive Advisors, Wellington Partners, and Fund+
Series B (2021): $25M led by V-Bio Ventures, Go Capital, EureKARE, Seroba Life Sciences Management, Théa Laboratories, Idinvest Partners, Fund+, Kurma Partners, Omnes Capital, and Turenne Capital
Series A (2025): $32M supported by UI Investissement, Bpifrance, Invus, and Novo Holdings
Key Investors in Coave Therapeutics
Novo Holdings
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in the life sciences sector.
Bpifrance
A French public investment bank that provides equity, credit, and guarantees to support the innovation and international growth of domestic companies.
UI Investissement
A specialized investment firm that partners with small and medium-sized French businesses to provide the capital and strategic support necessary for scaling operations.
What's next for Coave Therapeutics?
Looking ahead, the recent capital injection will be pivotal for Coave Therapeutics as it transitions its lead candidates further into clinical trials. The strategic focus will likely remain on optimizing manufacturing processes and expanding the reach of its gene therapy pipeline. With the backing of experienced life science investors, the company is expected to prioritize data generation and regulatory engagement, which are essential for validating its therapeutic approach. As the firm scales its operations, it will likely continue to explore collaborative opportunities that enhance its research capabilities and commercial potential in the global biotechnology landscape.
See full Coave Therapeutics company page
